

Persistent neuropsychiatric symptoms after COVID-19: a systematic review and meta-analysis.

James B. Badenoch*, Emma R. Rengasamy*, Cameron J. Watson, Katrin Jansen, Stuti Chakraborty, Ritika D. Sundaram, Danish Hafeez, Ella Burchill, Aman Saini, Lucretia Thomas, Benjamin Cross, Camille K. Hunt, Isabella Conti, Sylvia Ralovska, Zain Hussain, Matthew Butler, Thomas A. Pollak, Ivan Koychev, Benedict D. Michael, Heinz Holling, Timothy R. Nicholson, Jonathan P. Rogers[□], Alasdair G. Rooney[□], for the SARS-CoV-Neuro Collaboration.

* Joint first authors [□] Joint last authors

Correspondence to:

Dr AG Rooney, Centre for Clinical Brain Sciences, Chancellor's Building, Edinburgh BioQuarter, 49 Little France Crescent, Edinburgh, EH16 4SB. Email: ally.rooney@ed.ac.uk.

Author affiliations (in order)

JB Badenoch, BSc. Medical School, University of Birmingham, Birmingham, UK.

ERR Rengasamy, MBBCh. Cwm Taf Morgannwg University Health Board, Wales, UK.

CJ Watson, MBBCh. Preventive Neurology Unit, Queen Mary University of London, London, UK. Barts Health NHS Trust, London, UK.

K Jansen, MSc. Department of Psychology, University of Münster, Münster, Germany.

S Chakraborty, BOT, Department of Physical Medicine and Rehabilitation, Christian Medical College and Hospital, Vellore, India.

RD Sundaram, BSc. School of Medicine, University of Glasgow, Glasgow, UK.

D Hafeez, BSc. School of Medical Sciences, University of Manchester, Manchester, UK.

E Burchill, BSc, Faculty of Life Sciences and Medicine, King's College London, London, UK.

A Saini, University College London Medical School, London, UK.

L Thomas, Medical School, University of Birmingham, Birmingham, UK.

B Cross, MBChB, East Lancashire Hospitals NHS Trust, Blackburn, UK.

CK Hunt, MSc. MS & NMO Clinical Trials Group, Division of Neurology, Department of Medicine, Faculty of Medicine, University of British Columbia, Vancouver, B.C., Canada.

I Conti, BSc, School of Medicine, Dentistry and Biomedical Sciences, Queen's University Belfast, Belfast, UK.

S Ralovska, MD, Department of Neurology, Psychiatry, Physiotherapy and Rehabilitation, Preventive Medicine, and Public Health, Sofia University "St. Kliment Ohridski".

Z Hussain, MBChB, School of Medicine, University of Edinburgh, Edinburgh, UK.

M Butler, MRCPsych. Institute of Psychiatry, Psychology and Neuroscience, King's College, London, UK.

TA Pollak, PhD. Institute of Psychiatry, Psychology and Neuroscience, King's College, London, UK.

I Koychev, MRCPsych. Department of Psychiatry, University of Oxford, Oxford, UK.

BD Michael, PhD. Institute for Infection, Veterinary, and Ecological Sciences, University of Liverpool, UK; NIHR HPRU for Emerging and Zoonotic Infection, Liverpool, UK; The Walton Centre NHS Foundation Trust, Liverpool, UK

Prof H Holling, Department of Psychology, University of Münster, Münster, Germany.

TR Nicholson, PhD. Institute of Psychiatry, Psychology and Neuroscience, King's College, London, UK.

JP Rogers, MRCPsych. Division of Psychiatry, University College London, London, UK; South London and Maudsley NHS Foundation Trust, London, UK.

AG Rooney, PhD. Centre for Clinical Brain Sciences, The University of Edinburgh, Edinburgh, UK; The Robert Fergusson Unit, Royal Edinburgh Hospital, Edinburgh, UK.

SUMMARY

Background: The nature and extent of persistent neuropsychiatric symptoms after COVID-19 are not established. To help inform mental health service planning in the pandemic recovery phase, we systematically determined the prevalence of neuropsychiatric symptoms in survivors of COVID-19.

Methods: For this pre-registered systematic review and meta-analysis (PROSPERO ID CRD42021239750) we searched PubMed, EMBASE, CINAHL and PsycINFO to 20th February 2021, plus our own curated database. We included peer-reviewed studies reporting neuropsychiatric symptoms at post-acute or later time-points after COVID-19 infection, and in control groups where available. For each study a minimum of two authors extracted summary data. For each symptom we calculated a primary pooled prevalence using generalised linear mixed models. Heterogeneity was measured with I^2 . Subgroup analyses were conducted for COVID-19 hospitalisation, severity, and duration of follow-up.

Findings: From 2,844 unique titles we included 51 studies ($n=18,917$ patients). The mean duration of follow-up after COVID-19 was 77 days (range 14-182 days). Study quality was generally moderate. The most frequent neuropsychiatric symptom was sleep disturbance (pooled prevalence=27.4% [95%CI 21.4-34.4%]), followed by fatigue (24.4% [17.5-32.9%]), objective cognitive impairment (20.2% [10.3-35.7%]), anxiety (19.1% [13.3-26.8%]), and post-traumatic stress (15.7% [9.9-24.1%]). Only two studies reported symptoms in control groups, both reporting higher frequencies in Covid-19 survivors versus controls. Between-study heterogeneity was high ($I^2=79.6\%-98.6\%$). There was little or no evidence of differential symptom prevalence based on hospitalisation status, severity, or follow-up duration.

Interpretation: Neuropsychiatric symptoms are common and persistent after recovery from COVID-19.

The literature on longer-term consequences is still maturing, but indicates a particularly high frequency of insomnia, fatigue, cognitive impairment, and anxiety disorders in the first six months after infection.

Funding:

JPR is supported by the Wellcome Trust (102186/B/13/Z).

IK is funded through the NIHR (Oxford Health Biomedical Research Facility, Development and Skills Enhancement Award) and the Medical Research Council (Dementias Platform UK and Deep and Frequent Phenotyping study project grants).

HH is funded by the German Research Foundation (DFG, Grant: HO 1286/16-1).

The funders played no role in the design, analysis or decision to publish.

RESEARCH IN CONTEXT

Evidence before this study

Neuropsychiatric symptoms like cognitive impairment, fatigue, insomnia, depression and anxiety can be highly disabling. Recently there has been increasing awareness of persistent neuropsychiatric symptoms after COVID-19 infection, but a systematic synthesis of these symptoms is not available. In this review we searched five databases up to 20th February 2021, to establish the pooled prevalence of individual neuropsychiatric symptoms up to six months after COVID-19.

Added value of this study

This study establishes which of a range of neuropsychiatric symptoms are the most common after COVID-19. We found high rates in general, with little convincing evidence that these symptoms lessen in frequency during the follow-up periods studied.

Implications

Persistent neuropsychiatric symptoms are common and appear to be limited neither to the post-acute phase, nor to recovery only from severe COVID-19. Our results imply that health services should plan for high rates of requirement for multidisciplinary services (including neurological, neuropsychiatric and psychological management) as populations recover from the COVID-19 pandemic.

INTRODUCTION

Early in the COVID-19 pandemic, neuropsychiatric symptoms were identified as a prominent feature of coronavirus outbreaks. (1,2) Analyses subsequently confirmed many neuropsychiatric manifestations of acute infection with SARS-CoV-2, with non-specific symptoms such as fatigue and headache the most commonly studied and reported in the early literature. (3) Studies assessing the prevalence of depression, anxiety, and post-traumatic stress in acute COVID-19 suggested specific psychiatric morbidity. The degree of persistence of neuropsychiatric symptoms in the post-acute and chronic phases after infection, however, remained far from clear.

Persistent symptoms after COVID-19 illness have been called “Long COVID”. (4–7) The point of onset of Long COVID is imprecisely defined and has been proposed to range from three to twelve weeks after infection. (8) Separately, UK guidelines conceptualise symptoms persisting between four and twelve weeks after infection as ‘ongoing symptomatic COVID-19’, with ‘post COVID-19 syndrome’ thereafter. (9) However it is defined, Long COVID is considered a multi-system disorder with most likely several distinct pathological mechanisms. (10–12) These uncertainties of definitions, terminology, and mechanism reflect the early stage of our knowledge about persisting symptoms after COVID-19, and in particular the lack of systematised descriptions of different components of the syndrome.

From a mental health perspective, emerging reports suggest a high frequency of neuropsychiatric symptoms after infection with COVID-19. These reports emphasise fatigue, cognitive dysfunction and sleep disorders, with increased rates of newly-diagnosed mood or anxiety disorders, and dementia. (13–15) Whether and how these neuropsychiatric sequelae are influenced by the severity of initial illness, or by the duration since COVID-19, is not known. Given the signals however, it seems likely that clinical services for COVID-19 survivors (8,16,17) will benefit from a synthesis of knowledge concerning the nature and extent of its neuropsychiatric complications. Previous analyses either did not focus specifically on these outcomes (18) or have been superseded by the rapid growth in research. (19)

We therefore aimed to estimate the prevalence of persistent neuropsychiatric symptoms in survivors of COVID-19. In secondary analyses we aimed to identify predictors of symptom prevalence. We hypothesised that persistent neuropsychiatric symptoms would be common among survivors of COVID-19, particularly in those with a more severe form of the illness (i.e. those that have required hospitalisation or intensive care), and would lessen in frequency as time passed after infection.

METHODS

We conducted a systematic review and meta-analysis based on a pre-registered protocol (PROSPERO ID CRD42021239750) reported according to PRISMA guidelines. (20) A detailed list of author contributions is provided (Table S1).

Search strategy

We searched Ovid MEDLINE(R) and Epub Ahead of Print, In-Process and Other Non-Indexed Citations and Daily, EMBASE (via Ovid), APA PsycInfo (via OVID) and CINAHL (via EBSCO) from 1st January 2020 to 20th February 2021. We adapted a previously published, librarian-designed search strategy for post-acute, persisting, or Long COVID. (21) To maximise sensitivity, our search strategy (Supplemental Methods) did not specify neuropsychiatric terms. We further examined our weekly-curated database of COVID-19 neurology and neuropsychiatry research (22) for any papers that were missed by the search strategy, and screened the reference lists of relevant systematic reviews published at the time of our primary search. (18,19)

Eligibility criteria

We included any observational study reporting persistent neuropsychiatric symptoms in adults (aged 18+ years), with a history of PCR-confirmed or clinically suspected SARS-CoV-2 infection. We defined “persistence” of symptoms differently for hospitalised and community-based samples. In hospitalised samples, we considered persistent symptoms as those present after hospital discharge, because discharged individuals are generally beyond the acute illness phase. In community-based samples, which lacked a discharge date, we considered persistent symptoms as those still present at least four weeks after the onset of symptoms or a positive PCR test.

We adopted a definition of “neuropsychiatric” symptoms proposed by patient-led research in this area. (15) We studied: affective symptoms (specifically anxiety and panic attacks, depression, and mania); hallucinations; sleep disturbance; objectively reported cognitive impairment (i.e through standardised cognitive tests); subjective cognitive impairment (such as patient report of ‘brain fog’ or other lay terms);

sensorimotor symptoms (such as paraesthesia, numbness, or weakness of specific body parts); dizziness and vertigo; headache; changes in speech or language; and changes in taste or smell. We added fatigue, which in our experience is commonly encountered in Long COVID clinics, and post-traumatic stress disorder or symptoms (PTSD/PTSS), which are frequently reported after COVID-19 (Box 1).

Box 1 about here

We excluded studies which did not report original data; where patients were not infected (or presumed infected) with SARS CoV-2; had fewer than 10 COVID-19 patients; reported no post-discharge data (hospitalised samples) or no timepoints longer than 4 weeks post-diagnosis (community samples); did not report any of the neuropsychiatric symptoms listed above; were not in the English language; were preclinical (animal/laboratory-based); or had not been peer-reviewed. In addition and considering our main aim, studies were only eligible if their design permitted, in our opinion, a reasonably generalisable estimation of point prevalence to the wider population. On this basis for example we excluded studies in which participants were eligible solely because of predetermined characteristics (e.g., the presence of neurological symptoms), had been discharged to ongoing inpatient rehabilitation for persisting symptoms, or were primarily drawn from statistically enriched samples such as support groups designed for people with persisting symptoms. Senior authors (AR/JR) discussed and agreed decisions about eligibility taken on this basis (see also Results).

Screening and data extraction

Screening of titles, abstracts, and full text was conducted by a minimum of two authors each blinded to the other's ratings using Rayyan (www.rayyan.ai). Lead authors (AR/JR/JB) resolved assessment discrepancies. For each eligible study data were extracted to a customised spreadsheet by one reviewer, then checked for accuracy by a second reviewer.

We aimed to extract all usable data for primary and secondary analyses. For instance, if a study reported data on the total population plus a breakdown of the same data for individual subgroups, we extracted each group (total population, subgroup 1, subgroup 2, etc) separately to the database. In the primary

analysis we only included data from the total population of each study. In order to qualify for a subgroup analysis, we took the conservative position that a study had to report extractable data on a completely homogeneous subgroup (e.g. we would not label studies reporting a combined 95% community and 5% hospitalised patients as 'community' samples; such a study would instead be excluded from the 'hospital vs community' secondary analysis). Where a study reported multiple time-points we included only the longest follow-up time-point. Where data were presented in a way which did not meet our purposes we contacted study investigators to request clarification. The quality of each study was graded using the Newcastle-Ottawa Scale by a minimum of two authors working independently. A full list of data fields and outcomes extracted is presented in Suppl Table 2.

Outcomes

The primary outcome was the pooled prevalence of each neuropsychiatric symptom, using estimates of point prevalence where available. We recorded symptoms however defined or measured by study investigators, including on the basis of patient self-report, clinical interview, case-note review, or rating scale. Where rating scales were used to quantify symptoms, we noted the specific scale and threshold applied. Where symptoms were characterised as a dichotomous variable (present/absent), including for patients scoring above a rating scale threshold, we recorded the relative frequency ("n affected in study" divided by "n infected with SARS-CoV-2"). Where symptoms were reported as continuous or ordinal variables (e.g., using rating scales) *and* where such data were available for both COVID-19 patients and a control group, we intended to calculate and then pool the Standardised Mean Differences. Studies reporting continuous or ordinal variables in COVID-19 populations only were summarised narratively in a table.

Primary analysis

We conducted the primary analysis on every neuropsychiatric symptom reported by three or more studies. We pooled results based on random-effects meta-analysis, using the metafor package in R version 4.0.2 (23) to calculate generalised linear mixed models for each prevalence outcome, (24,25)

before using the inverse variance method with the Freeman-Tukey double arcsine transformation as a comparative sensitivity analysis. (26) We assessed between-study heterogeneity using the I^2 statistic. For interpretation we reported forest plots with 95% confidence intervals.

Around one fifth of eligible studies reported multiple types of cognitive dysfunction. Post-hoc we separated cognitive dysfunction into 'objective' and 'subjective' dysfunction. We defined objective cognitive dysfunction as revealed by a cognitive assessment screening tool (e.g. MMSE, MoCA, or similar). All other forms of cognitive dysfunction (such as patient self-report of memory problems, 'brain fog', or similar) were classed as subjective. A small number of studies reported >1 symptom of subjective cognitive dysfunction (for example, self-reported "memory disorder" and "concentration disorder", (27). In such cases we included the subjective cognitive symptom with the highest prevalence.

Secondary analyses

A priori we intended to conduct secondary analyses examining for differences in neuropsychiatric symptom prevalence between a) COVID-19 patients and control groups, b) COVID-19 patients whose diagnosis was PCR-confirmed and those in whom it was not, c) hospitalised and community samples, and d) different time-points following a positive test for SARS-CoV-2 (specifying <12 weeks versus 12 or more weeks to align with a key timepoint in NICE guidance for post COVID-19 syndrome. (9) Following data extraction we discovered that analyses (a) and (b) could not be run owing to a dearth of studies with control groups or non-PCR-confirmed cases, and the wording of (d) was too restrictive (excluding for instance the many studies measuring duration of symptoms from the date of hospital discharge, rather than from the date of a positive test).

We added two post-hoc quantitative secondary analyses to reflect the balance of the literature. The first of these was a further evaluation of disease severity. We had found that some studies reported intensive care (ICU) vs non-ICU admission whereas others used the WHO severity scale. (28) We grouped these studies as follows: ICU admission OR reported as having WHO 'critical' or 'severe' COVID-19, versus

hospitalised patients declared as not admitted to ICU. The second analysis was a broadening of the scope of 'duration' to include the 19 studies anchoring on discharge (<12 versus 12+ weeks). We did not combine studies anchoring on the date of PCR testing with those using the date of hospital discharge owing to the wide variability in duration of COVID-19 hospital admissions. However, post-hoc we did combine studies using the date of PCR testing with those using the date of onset of symptoms, which we reasoned were often likely to be close together in time. In a post-hoc qualitative analysis we inspected scatterplots of reported symptom prevalence against time (separately for: dichotomised <12/12+ weeks, mean duration, and median duration of follow-up for all symptoms).

We required a minimum of two studies in each sub-group being compared and a minimum of five eligible studies overall per analysis. Every secondary analysis conducted on each symptom is listed in Suppl Table 3.

RESULTS

Study selection

The search yielded 4385 studies. After de-duplication we screened the titles and abstracts of 2861 studies, the full text of 428 studies, and included 51 eligible studies (Figure 1, Table S4 (27,29–78). Brief reasons for excluding studies are listed in Table S5. We contacted the authors of seven studies which did not report extricable prevalence data; three replied with usable data.

Figure 1 about here

Population and study characteristics

The 51 included studies reported data on a total population $n=18917$ individuals (sample size range 24–5879; median $n=134$), $n=15786$ (83.4%) of whom had COVID-19 confirmed by PCR. The mean age reported was 50.9 years (SD=9.4). The largest study ($n=5879$, 31.1% of entire sample) did not specify sex; of the remainder $n=6825$ (33.2%) of patients were specified male. Most patients ($n=9970$, 52.8%) were post-hospital discharge, $n=2957$ (15.7%) had been treated solely in the community, and in $n=5962$ (31.5%) the location of care was unstated. A metric of COVID-19 severity was reported by half (26/51) of studies but the number of severe cases declared was often small: only $n=1245/18917$ (6.6%) of patients in the full sample were specified as having had ICU admission or WHO critical/severe COVID-19. Ethnicity was reported for only $n=2378/18917$ (12.6%) patients, in whom $n=1172$ (49.3% of specified) were White. Most studies originated in China (13 studies) followed by Italy (six studies), the USA (5 studies), and the UK (5 studies) (Figure 2, Table 1).

Figure 2 and Table 1 about here

Most studies (43/51) had a cohort design. Only 2/51 reported symptoms in a control group. The mean duration of followup was 77 days (range 14–182 days). Most studies (30/51) examined patients at <12 weeks with 19/51 examining a time-point at 12+ weeks. There was little consensus on the anchor point for calculating follow-up duration: 23 studies reported duration since hospital discharge, 16 studies

reported duration post-symptom onset or post-PCR testing, 11 used another definition (e.g. date of virological clearance), and two did not specify the anchor point. Study quality assessed using the Newcastle-Ottawa Scale was low in seven studies, medium in 39, and high in five (Figure S1, Table S6).

Prevalence of neuropsychiatric symptoms

The most frequent neuropsychiatric symptom was sleep disturbance (pooled prevalence=27.4% [95%CI 21.4-34.4%]), followed by fatigue (24.4% [17.5-32.9%]), objectively measured cognitive impairment (20.2% [10.3-35.7%]), anxiety (19.1% [13.3-26.8%]), and post-traumatic stress (15.7% [9.9-24.1%]) (Figure 3, Table 2). More classically 'neurological' symptoms such as dysgeusia, headache, sensorimotor disturbance, and dizziness/vertigo were less frequent but present in non-negligible amounts (pooled prevalence <10% for each). Speech and language symptoms, panic attacks, mania, and hallucinations could not be meta-analysed due to an absence of studies. Heterogeneity was high ($I^2=79.6\%-98.6\%$, Table 2). The results of the sensitivity analysis were in general similar to the results of the main analysis in terms of the point estimate of prevalence, confidence interval boundaries and heterogeneity (Table S7).

Figure 3 and Table 2 about here

Only two studies reported symptoms in control groups, both drawn from healthy populations and neither formally matched to the respective COVID-19 groups. (36,51) Each reported higher frequencies of sleep disorder, fatigue, dizziness, depression, anxiety, and/or psychosis in COVID-19 survivors compared to controls (Table S8).

Secondary analyses

With the exception of anxiety, which was reported more frequently in non-hospitalised samples, there was no evidence of a differential prevalence of any symptom among hospitalised versus non-hospitalised samples (eight symptoms eligible to be tested), nor among patients admitted to ICU/having WHO 'critical'

or 'severe' illness versus those not requiring ICU (six symptoms). Similarly there was no evidence of difference among patients surveyed <12 weeks versus 12+ weeks post-discharge (eight symptoms eligible to be tested), nor the same time-points post-symptom onset/PCR test (four symptoms, Figure 4, Table 3). Scatterplots of symptom prevalence reported by individual studies, plotted against duration since COVID-19, are presented in Figures S2 and S3.

Figure 4 and Table 3 about here

DISCUSSION

In this systematic review and meta-analysis, we found that neuropsychiatric symptoms are common and persistent after COVID-19. Sleep disorders and fatigue appear to be especially prevalent and may be experienced by as many as one in four patients. Anxiety and post-traumatic stress symptoms also seem particularly common, and cognitive impairment is often objectively detectable. Sensorimotor disturbances and dizziness or vertigo are less common but present in a non-negligible proportion of patients. The prevalence of these symptoms appears to be relatively stable across different points in the first six months, between hospitalised and community samples, and among hospitalised patients regardless of COVID-19 severity. There are knowledge gaps in the neuropsychiatric consequences of COVID-19 in patients who did not require hospital admission, the impact of ethnicity, and the course and frequency of symptoms in the longer term.

These findings should be interpreted cautiously. Three in five studies in this review reported symptoms within the NICE guideline-suggested threshold of twelve weeks for the post-acute phase. (9) Relatively few eligible community-based or ICU-admitted samples reported our outcomes of interest, making rounded conclusions about the impact of COVID-19 severity difficult to draw. If, in due course, significant symptomatic differences emerge from data comparing hospitalised and non-hospitalised patients, then there could be a case that the term “Long COVID” is best reserved for patients who weren’t hospitalised - or that a subspecifier could be useful to denote severity of initial respiratory and/or other symptoms. Non-hospitalised patients were in the minority in this review (with only 15.7% confirmed as such), reflecting the early research focus on hospitalised patients. However, non-hospitalised patients were the majority (91.6%) in a recent large patient-led survey. In our view patient perspectives on terminology for this initially patient-driven disorder should be considered equally alongside those of clinicians and researchers. (15)

Most studies tended to report outcomes based on patient self-report rather than structured clinical assessments. Meanwhile the lack of active control groups meant that the specific contribution of COVID-

19 to such neuropsychiatric symptoms remains unknown. It is possible that the breadth and frequency of these symptoms represent the natural trajectory of recovery from a serious viral illness. The extent to which neuropsychiatric symptoms were new-onset, versus relapse of an existing condition, was not reported. Nor did we formally appraise the eligibility of 15 studies in which there was no English-language article available.

Our pooled data however imply frequent neuropsychiatric morbidity among COVID-19 survivors in the post-acute phase. These observations echo a recent large study associating COVID-19 with an increased risk of neuropsychiatric clinical diagnoses in the first six months, including first-onset insomnia, mood, anxiety, or psychotic disorders, and dementia. (14) The same study found a higher risk of such disorders after COVID-19 compared to other respiratory tract illnesses, indicating that at least some of the apparent neuropsychiatric burden may be COVID-19-specific. Notably the trajectory of accrual of new psychiatric diagnoses flattened only slightly in the first six months, supporting the hypothesis that neuropsychiatric symptoms persist within this timeframe. Our data also broadly support the aforementioned patient-led survey, of 3762 mainly non-hospitalised COVID-19 patients, (15) in which fatigue, self-reported cognitive dysfunction, and other neuropsychiatric symptoms (e.g. dizziness and sensorimotor symptoms) were highly prevalent. Owing to the self-selected nature of that study population - which was recruited mostly via Long COVID support groups and similar organisations - their data would be ineligible to contribute to generalisable estimates of community prevalence in the current meta-analysis; a characteristic which illustrates the difficulty of finding generalisable community-based samples. (79)

The extent to which neuropsychiatric symptom burden impacts upon clinical services remains to be seen, although structuring Long COVID services to be proactive in case identification and treatment seems sensible. It remains possible that the commonest symptoms, such as (in descending order of frequency) insomnia, fatigue, anxiety, cognitive impairment, post-traumatic stress, and depression may respond to physical and/or psychological treatments as they do in other conditions. (80–84) In some instances, persisting symptoms after COVID-19 may reflect initial direct tissue injury mechanisms (e.g. inflammation) overlapping with other or additional mechanisms (e.g. cognitive) as can be seen in other complex

disorders arising after illness like chronic pain. Multidisciplinary approaches are often appropriate for such disorders (85) including combinations of neurology, neurorehabilitation, neuropsychiatry, physiotherapy, occupational therapy and psychological input. Such approaches should be incorporated into the planning for 'Long Covid' services.

Our results identify areas for further research. Controlled studies are required to separate out the neuropsychiatric consequences of viral illness in general from those potentially specific to COVID-19 in particular. The impact of ethnicity and of COVID-19 severity remain to be clarified. Classical epidemiological approaches may be required to generate representative community-based samples, and longer-term follow-up is required. Emerging prospective, longitudinal, and multicentre studies will probe the characteristics and aetiology of persistent neuropsychiatric symptoms in patients with COVID-19. (86) Future trials meanwhile may examine treatments known to be effective in treating neuropsychiatric symptoms in other populations.

Conclusion

Neuropsychiatric symptoms are common and persistent after recovery from COVID-19. Sleep problems and fatigue predominate and appear to affect roughly one quarter of survivors. Cognitive impairment, anxiety, post-traumatic symptoms, and depression are also common in the first six months. There is as yet little evidence that these persisting symptoms relate to the severity of, or duration since, initial infection. Although more research is needed, these early signals suggest a high burden of neuropsychiatric symptoms among COVID-19 survivors. Multidisciplinary services should be resourced accordingly in the post-COVID era.

CONTRIBUTORS

JB, TRN, JR, MB, and AGR conceived the review. JB and ERR led the project. JB and AGR ran the searches. All authors bar CW, KJ, HH, MB, TP, IK, BM, and TRN extracted data. CW and KJ did the statistical analysis. AGR, JB, KJ, SC, and EB wrote the first draft of the report. All authors had the opportunity to comment and all approved the final version. HH, MB, TP, IK, BM, TRN, JPR, and AGR provided executive oversight and/or direct supervision. JB and AGR verified the data. All authors had full access to all the data in the study and had final responsibility for the decision to submit for publication.

DECLARATION OF INTERESTS

JPR held one advisory meeting with representatives from Promentis Pharmaceuticals regarding drug development. No payment made. JPR received payment from Alberta Psychiatric Association for lecturing at the Annual Scientific Conference.

IK receives a contribution towards his salary from the Medical Research Council (Dementias Platform UK grant), NIHR Oxford Health Biomedical Research Centre, NIHR Development and Skills Enhancement award. IK has received the following grants: Medical Research Council Deep and Frequent Phenotyping study project grant, Oxford Global Challenges Research Fund project grant, MRC-NIH Partnership in Neurodegeneration award. IK has received consulting fees from Mantrah Ltd, Sharp Tx Ltd, Cognetivity Ltd. He has served as an advisory board member and has stocks options in Mantrah Ltd and Sharp Tx Ltd.

DATA SHARING

Our full R code, and data, can be made available on reasonable request.

ACKNOWLEDGEMENTS

JPR is supported by the Wellcome Trust (102186/B/13/Z). IK is funded through the NIHR (Oxford Health Biomedical Research Facility, Development and Skills Enhancement Award) and the Medical Research Council (Dementias Platform UK and Deep and Frequent Phenotyping study project grants). HH is funded by the German Research Foundation (DFG, Grant: HO 1286/16-1).

FIGURE LEGENDS

Figure 1. PRISMA Flowchart.

Figure 2. Map of studies. Most studies originated in China, the USA, the UK, and Italy. Map created with mapchart.net.

Figure 3. Forest plots for individual neuropsychiatric symptoms, all studies. Symptoms are plotted individually. The point prevalence for individual studies is presented with 95% confidence intervals on the right hand side of each plot. The pooled prevalence and 95% confidence interval for that symptom is shown at the bottom of each plot.

Figure 4. Pooled symptom prevalence by subgroups. Four subgroup analyses are shown (major panels **A-C''**). Within each analysis symptoms which were eligible for analysis are plotted individually (identified in the right-hand tab on each minor panel). **A:** Comparison of pooled prevalence for studies reporting non-hospitalised versus hospitalised samples. **B:** Comparison of studies reporting patients who had non-ITU/non-severe versus ITU/critical/severe COVID-19. **C':** Comparison of studies reporting duration of follow-up shorter than 12 weeks post-hospital discharge, versus those reporting longer follow-up. **C'':** Comparison of studies reporting duration of follow-up shorter than 12 weeks since onset of COVID-19 symptoms, versus those reporting longer follow-up.

Figure S1. Histogram of study quality scores. The final Newcastle-Ottawa Scale (NOS) score for each included study is plotted in a histogram (total n=51 studies).

Figure S2. Scatterplots of symptom prevalence over time (dichotomised at 12 weeks). Each individual symptom is displayed in a minor panel. The point prevalence of that symptom in each individual study is represented by an individual data point. Studies are grouped according to their duration of follow-up (<12 versus 12+ weeks). The anchor point for follow-up duration (since the onset of symptoms/PCR testing, or since discharge) is indicated by the shape of each data point (see legend). In general there is little evidence of differential prevalence according to duration of follow-up.

Figure S3. Scatterplots of symptom prevalence over time (continuous). Qualitative illustration of point prevalence estimates of individual symptoms (each minor panel) in individual studies (each data point). The anchor for follow-up duration is indicated by the shape of each point. Due to the relatively small number of studies for most symptoms, a quantitative analysis (e.g. a regression line) has not been conducted. **A'**: Scatterplots of studies reporting *mean* duration of follow-up. **A''**: Scatterplots of studies reporting *median* duration of follow-up. In general there is little qualitative evidence of a marked change in the reported point prevalence of symptoms with increasing duration since COVID-19.

LIST OF TABLES

Table 1. Characteristics of included studies.

Table 2. Pooled prevalence of individual neuropsychiatric symptoms (data for Fig 3).

Table 3. Pooled symptom prevalence by subgroups (data for Fig 4).

Table S1. List of author contributions.

Table S2. Full list of data fields extracted from eligible studies.

Table S3. All secondary analyses conducted on each symptom.

Table S4. Summary of included studies.

Table S5. Rationale for excluding studies

Table S6. Ranking of study quality.

Table S7. Meta-analysis sensitivity analysis.

Table S8. Comparison of studies including control group.

REFERENCES

1. Wu Y, Xu X, Chen Z, Duan J, Hashimoto K, Yang L, et al. Nervous system involvement after infection with COVID-19 and other coronaviruses. *Brain Behav Immun*. 2020 Jul;87:18–22.
2. Rogers JP, Chesney E, Oliver D, Pollak TA, McGuire P, Fusar-Poli P, et al. Psychiatric and neuropsychiatric presentations associated with severe coronavirus infections: a systematic review and meta-analysis with comparison to the COVID-19 pandemic. *Lancet Psychiatry*. 2020 Jul;7(7):611–27.
3. Rogers JP, Watson C, Badenoch J, Cross B, Butler M, Song J, et al. The neurology and neuropsychiatry of COVID-19: a systematic review and meta-analysis of the early literature reveals frequent CNS manifestations and key emerging narratives [Internet]. *Psychiatry and Clinical Psychology*; 2021 Feb [cited 2021 Apr 19]. Available from: <http://medrxiv.org/lookup/doi/10.1101/2021.02.24.21252335>
4. Lokugamage A, Taylor S, Rayner C. Patients' experiences of "longcovid" are missing from the NHS narrative [Internet]. *the bmj opinion*. 2020 [cited 2021 Apr 23]. Available from: <https://blogs.bmj.com/bmj/2020/07/10/patients-experiences-of-longcovid-are-missing-from-the-nhs-narrative/>
5. Alwan NA, Attree E, Blair JM, Bogaert D, Bowen M-A, Boyle J, et al. From doctors as patients: a manifesto for tackling persisting symptoms of covid-19. *BMJ*. 2020 Sep 15;370:m3565.
6. Perego E, Callard F, Stras L, Melville-Johannesson B, Pope R, Alwan NA. Why we need to keep using the patient made term "Long Covid" [Internet]. *the bmj opinion*. 2020 [cited 2021 Apr 23]. Available from: <https://blogs.bmj.com/bmj/2020/10/01/why-we-need-to-keep-using-the-patient-made-term-long-covid/>
7. Callard F, Perego E. How and why patients made Long Covid. *Soc Sci Med* 1982. 2021 Jan;268:113426.
8. Greenhalgh T, Knight M, A'Court C, Buxton M, Husain L. Management of post-acute covid-19 in primary care. *BMJ*. 2020 Aug 11;m3026.
9. National Institute for Health and Care Excellence. COVID-19 rapid guideline: managing the long-term effects of COVID-19 NICE guideline [NG188] [Internet]. National Institute for Health and Care Excellence; 2020 [cited 2021 Apr 23]. Available from: <https://www.nice.org.uk/guidance/ng188>
10. Puntmann VO, Carerj ML, Wieters I, Fahim M, Arendt C, Hoffmann J, et al. Outcomes of Cardiovascular Magnetic Resonance Imaging in Patients Recently Recovered From Coronavirus Disease 2019 (COVID-19). *JAMA Cardiol*. 2020 Nov 1;5(11):1265.
11. Pan F, Ye T, Sun P, Gui S, Liang B, Li L, et al. Time Course of Lung Changes at Chest CT during Recovery from Coronavirus Disease 2019 (COVID-19). *Radiology*. 2020 Jun;295(3):715–21.
12. Galván Casas C, Català A, Carretero Hernández G, Rodríguez-Jiménez P, Fernández-Nieto D, Rodríguez-Villa Lario A, et al. Classification of the cutaneous manifestations of COVID-19: a rapid prospective nationwide consensus study in Spain with 375 cases. *Br J Dermatol*. 2020 Jul;183(1):71–7.

13. Pilotto A, Cristillo V, Piccinelli SC, Zoppi N, Bonzi G, Sattin D, et al. Long-term neurological manifestations of COVID-19: prevalence and predictive factors [Internet]. *Neurology*; 2021 Jan [cited 2021 Apr 19]. Available from: <http://medrxiv.org/lookup/doi/10.1101/2020.12.27.20248903>
14. Taquet M, Geddes JR, Husain M, Luciano S, Harrison PJ. 6-month neurological and psychiatric outcomes in 236 379 survivors of COVID-19: a retrospective cohort study using electronic health records. *Lancet Psychiatry*. 2021 Apr 1;
15. Davis, Hannah E., Assaf, G S, McCorkell, Lisa, Wei, Hannah, Low, Ryan J. L., Re'em, Yochai, et al. Characterizing Long COVID in an International Cohort: 7 Months of Symptoms and Their Impact [Internet]. *Infectious Diseases*; 2020 Dec [cited 2021 Apr 19]. Available from: <https://www.medrxiv.org/content/10.1101/2020.12.24.20248802v2>
16. NHS England. Long COVID patients to get help at more than 60 clinics. 2020 Dec 18 [cited 2021 Apr 23]; Available from: <https://www.england.nhs.uk/2020/12/long-covid-patients-to-get-help-at-more-than-60-clinics/>
17. Nabavi N. Long covid: How to define it and how to manage it. *BMJ*. 2020 Sep 7;m3489.
18. Lopez-Leon S, Wegman-Ostrosky T, Perelman C, Sepulveda R, Rebolledo P, Cuapio A, et al. More Than 50 Long-Term Effects of COVID-19: A Systematic Review and Meta-Analysis. *Res Sq*. 2021 Mar 1;
19. Michelen M, Manoharan L, Elkheir N, Cheng V, Dagens D, Hastie C, et al. Characterising long-term covid-19: a rapid living systematic review [Internet]. *Public and Global Health*; 2020 Dec [cited 2021 Apr 23]. Available from: <http://medrxiv.org/lookup/doi/10.1101/2020.12.08.20246025>
20. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. *BMJ*. 2021 Mar 29;372:n71.
21. Ludvigsson JF. Case report and systematic review suggest that children may experience similar long-term effects to adults after clinical COVID-19. *Acta Paediatr Oslo Nor* 1992. 2021 Mar;110(3):914–21.
22. Butler M, Watson C, Rooney AG, Song J, Badenoch J, Cross B, et al. The Neurology and Neuropsychiatry of COVID-19 [Internet]. *Journal of Neurology, Neurosurgery and Psychiatry*. [cited 2021 Apr 23]. Available from: <https://blogs.bmj.com/jnnp/2020/05/01/the-neurology-and-neuropsychiatry-of-covid-19/>
23. Viechtbauer W. Conducting Meta-Analyses in R with the **metafor** Package. *J Stat Softw* [Internet]. 2010 [cited 2021 Apr 23];36(3). Available from: <http://www.jstatsoft.org/v36/i03/>
24. Hamza TH, van Houwelingen HC, Stijnen T. The binomial distribution of meta-analysis was preferred to model within-study variability. *J Clin Epidemiol*. 2008 Jan;61(1):41–51.
25. Stijnen T, Hamza TH, Özdemir P. Random effects meta-analysis of event outcome in the framework of the generalized linear mixed model with applications in sparse data. *Stat Med*. 2010 Dec 20;29(29):3046–67.
26. Freeman MF, Tukey JW. Transformations Related to the Angular and the Square Root. *Ann Math Stat*. 1950 Dec;21(4):607–11.
27. Klein H, Asseo K, Karni N, Benjamini Y, Nir-Paz R, Muszkat M, et al. Onset, duration and unresolved symptoms, including smell and taste changes, in mild COVID-19 infection: a cohort study in Israeli patients. *Clin Microbiol Infect Off Publ Eur Soc Clin Microbiol Infect Dis*. 2021 Feb 16;
28. WHO Headquarters (HQ). COVID-19 Clinical management: living guidance [Internet]. WHO; 2021 [cited 2021 Apr 27]. Available from: <https://www.who.int/publications/i/item/WHO-2019-nCoV-clinical-2021-1>
29. De Lorenzo R, Conte C, Lanzani C, Benedetti F, Roveri L, Mazza MG, et al. Residual clinical damage after COVID-19: A retrospective and prospective observational cohort study. *Adrish M, editor. PLOS ONE*. 2020 Oct 14;15(10):e0239570.
30. Ju Y, Chen W, Liu J, Yang A, Shu K, Zhou Y, et al. Effects of centralized isolation vs. home isolation on psychological distress in patients with COVID-19. *J Psychosom Res*. 2021 Apr;143:110365.
31. Simani L, Ramezani M, Darazam IA, Sagharichi M, Aalipour MA, Ghorbani F, et al. Prevalence and correlates of chronic fatigue syndrome and post-traumatic stress disorder after the outbreak of the COVID-19. *J Neurovirol*. 2021 Feb;27(1):154–9.
32. Niklassen AS, Draf J, Huart C, Hintschich C, Bocksberger S, Trecca EMC, et al. COVID 19: Recovery from Chemosensory Dysfunction. A Multicentre study on Smell and Taste. *The Laryngoscope*. 2021 May;131(5):1095–100.
33. Tomasoni D, Bai F, Castoldi R, Barbanotti D, Falcinella C, Mulè G, et al. Anxiety and depression symptoms after virological clearance of COVID 19: A cross-sectional study in Milan, Italy. *J Med*

- Virol. 2021 Feb;93(2):1175–9.
34. Taboada M, Moreno E, Cariñena A, Rey T, Pita-Romero R, Leal S, et al. Quality of life, functional status, and persistent symptoms after intensive care of COVID-19 patients. *Br J Anaesth*. 2021 Mar;126(3):e110–3.
35. Bellan M, Soddu D, Balbo PE, Baricich A, Zeppego P, Avanzi GC, et al. Respiratory and Psychophysical Sequelae Among Patients With COVID-19 Four Months After Hospital Discharge. *JAMA Netw Open*. 2021 Jan 27;4(1):e2036142.
36. Oh TK, Park HY, Song I. Risk of psychological sequelae among coronavirus disease 2019 survivors: A nationwide cohort study in South Korea. *Depress Anxiety*. 2021 Feb;38(2):247–54.
37. Miyazato Y, Morioka S, Tsuzuki S, Akashi M, Osanai Y, Tanaka K, et al. Prolonged and Late-Onset Symptoms of Coronavirus Disease 2019. *Open Forum Infect Dis*. 2020 Nov 1;7(11):ofaa507.
38. Liang L, Yang B, Jiang N, Fu W, He X, Zhou Y, et al. Three-Month Follow-Up Study of Survivors of Coronavirus Disease 2019 after Discharge. *J Korean Med Sci*. 2020;35(47):e418.
39. Sonnweber T, Sahanic S, Pizzini A, Luger A, Schwabl C, Sonnweber B, et al. Cardiopulmonary recovery after COVID-19 – an observational prospective multi-center trial. *Eur Respir J*. 2020 Dec 10;2003481.
40. Garrigues E, Janvier P, Kherabi Y, Le Bot A, Hamon A, Gouze H, et al. Post-discharge persistent symptoms and health-related quality of life after hospitalization for COVID-19. *J Infect*. 2020 Dec;81(6):e4–6.
41. Afshar Y, Gaw SL, Flaherman VJ, Chambers BD, Krakow D, Berghella V, et al. Clinical Presentation of Coronavirus Disease 2019 (COVID-19) in Pregnant and Recently Pregnant People. *Obstet Gynecol*. 2020 Dec;136(6):1117–25.
42. He S, Tian J, Li X, Zhou Y, Xiao M, Zhang Y, et al. Positive RT-PCR Test Results in 420 Patients Recovered From COVID-19 in Wuhan: An Observational Study. *Front Pharmacol*. 2020 Oct 7;11:549117.
43. Akter F, Mannan A, Mehedi HMH, Rob MdA, Ahmed S, Salauddin A, et al. Clinical characteristics and short term outcomes after recovery from COVID-19 in patients with and without diabetes in Bangladesh. *Diabetes Metab Syndr Clin Res Rev*. 2020 Nov;14(6):2031–8.
44. Zhao Y, Shang Y, Song W, Li Q, Xie H, Xu Q, et al. Follow-up study of the pulmonary function and related physiological characteristics of COVID-19 survivors three months after recovery. *EClinicalMedicine*. 2020 Aug;25:100463.
45. D'Cruz RF, Waller MD, Perrin F, Periseleris J, Norton S, Smith L-J, et al. Chest radiography is a poor predictor of respiratory symptoms and functional impairment in survivors of severe COVID-19 pneumonia. *ERJ Open Res*. 2021 Jan;7(1):00655–2020.
46. Sun B, Tang N, Peluso MJ, Iyer NS, Torres L, Donatelli JL, et al. Characterization and Biomarker Analyses of Post-COVID-19 Complications and Neurological Manifestations. *Cells*. 2021 Feb 13;10(2):386.
47. Islam MdS, Ferdous MostZ, Islam US, Mosaddek ASMd, Potenza MN, Pardhan S. Treatment, Persistent Symptoms, and Depression in People Infected with COVID-19 in Bangladesh. *Int J Environ Res Public Health*. 2021 Feb 5;18(4):1453.
48. Huang C, Huang L, Wang Y, Li X, Ren L, Gu X, et al. 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study. *The Lancet*. 2021 Jan;397(10270):220–32.
49. Moreno-Pérez O, Merino E, Leon-Ramírez J-M, Andres M, Ramos JM, Arenas-Jiménez J, et al. Post-acute COVID-19 syndrome. Incidence and risk factors: A Mediterranean cohort study. *J Infect*. 2021 Mar;82(3):378–83.
50. Halpin SJ, McIvor C, Whyatt G, Adams A, Harvey O, McLean L, et al. Postdischarge symptoms and rehabilitation needs in survivors of COVID-19 infection: A cross-sectional evaluation. *J Med Virol*. 2021 Feb;93(2):1013–22.
51. Xiong Q, Xu M, Li J, Liu Y, Zhang J, Xu Y, et al. Clinical sequelae of COVID-19 survivors in Wuhan, China: a single-centre longitudinal study. *Clin Microbiol Infect*. 2021 Jan;27(1):89–95.
52. Rosales-Castillo A, García de los Ríos C, Mediavilla García JD. Persistencia de manifestaciones clínicas tras la infección COVID-19: importancia del seguimiento. *Med Clínica*. 2021 Jan;156(1):35–6.
53. Jacobs LG, Gourni Paleoudis E, Lesky-Di Bari D, Nyirenda T, Friedman T, Gupta A, et al. Persistence of symptoms and quality of life at 35 days after hospitalization for COVID-19 infection. Madeddu G, editor. *PLOS ONE*. 2020 Dec 11;15(12):e0243882.

54. Daher A, Balfanz P, Cornelissen C, Müller A, Bergs I, Marx N, et al. Follow up of patients with severe coronavirus disease 2019 (COVID-19): Pulmonary and extrapulmonary disease sequelae. *Respir Med*. 2020 Nov;174:106197.
 55. Arnold DT, Hamilton FW, Milne A, Morley AJ, Viner J, Attwood M, et al. Patient outcomes after hospitalisation with COVID-19 and implications for follow-up: results from a prospective UK cohort. *Thorax*. 2021 Apr;76(4):399–401.
 56. Stavem K, Ghanima W, Olsen MK, Gilboe HM, Einvik G. Persistent symptoms 1.5–6 months after COVID-19 in non-hospitalised subjects: a population-based cohort study. *Thorax*. 2021 Apr;76(4):405–7.
 57. Petersen MS, Kristiansen MF, Hanusson KD, Danielsen ME, á Steig B, Gaini S, et al. Long COVID in the Faroe Islands: A Longitudinal Study Among Nonhospitalized Patients. *Clin Infect Dis*. 2020 Nov 30;ciaa1792.
 58. Boscolo-Rizzo P, Borsetto D, Fabbris C, Spinato G, Frezza D, Menegaldo A, et al. Evolution of Altered Sense of Smell or Taste in Patients With Mildly Symptomatic COVID-19. *JAMA Otolaryngol Neck Surg*. 2020 Aug 1;146(8):729.
 59. van den Borst B, Peters JB, Brink M, Schoon Y, Bleeker-Rovers CP, Schers H, et al. Comprehensive health assessment three months after recovery from acute COVID-19. *Clin Infect Dis*. 2020 Nov 21;ciaa1750.
 60. Carvalho-Schneider C, Laurent E, Lemaiguen A, Beauvils E, Bourbao-Tournois C, Laribi S, et al. Follow-up of adults with noncritical COVID-19 two months after symptom onset. *Clin Microbiol Infect*. 2021 Feb;27(2):258–63.
-
61. Mandal S, Barnett J, Brill SE, Brown JS, Denny EK, Hare SS, et al. 'Long-COVID': a cross-sectional study of persisting symptoms, biomarker and imaging abnormalities following hospitalisation for COVID-19. *Thorax*. 2021 Apr;76(4):396–8.
 62. Mazza MG, De Lorenzo R, Conte C, Poletti S, Vai B, Bollettini I, et al. Anxiety and depression in COVID-19 survivors: Role of inflammatory and clinical predictors. *Brain Behav Immun*. 2020 Oct;89:594–600.
 63. Pellaud C, Grandmaison G, Pham Huu Thien HP, Baumberger M, Carrel G, Ksouri H, et al. Characteristics, comorbidities, 30-day outcome and in-hospital mortality of patients hospitalised with COVID-19 in a Swiss area - a retrospective cohort study. *Swiss Med Wkly*. 2020 Jul 13;150:w20314.
 64. Lu Y, Li X, Geng D, Mei N, Wu P-Y, Huang C-C, et al. Cerebral Micro-Structural Changes in COVID-19 Patients – An MRI-based 3-month Follow-up Study. *EClinicalMedicine*. 2020 Aug;25:100484.
 65. Zhu S, Gao Q, Yang L, Yang Y, Xia W, Cai X, et al. Prevalence and risk factors of disability and anxiety in a retrospective cohort of 432 survivors of Coronavirus Disease-2019 (Covid-19) from China. Federici S, editor. *PLOS ONE*. 2020 Dec 17;15(12):e0243883.
 66. Jacobson KB, Rao M, Bonilla H, Subramanian A, Hack I, Madrigal M, et al. Patients with uncomplicated COVID-19 have long-term persistent symptoms and functional impairment similar to patients with severe COVID-19: a cautionary tale during a global pandemic. *Clin Infect Dis Off Publ Infect Dis Soc Am*. 2021 Feb 7;
 67. Sykes DL, Holdsworth L, Jawad N, Gunasekera P, Morice AH, Crooks MG. Post-COVID-19 Symptom Burden: What is Long-COVID and How Should We Manage It? *Lung*. 2021 Feb 11;
 68. van der Sar-van der Brugge S, Talman S, Boonman-de Winter L, de Mol M, Hoefman E, van Etten RW, et al. Pulmonary function and health-related quality of life after COVID-19 pneumonia. *Respir Med*. 2021 Jan;176:106272.
 69. Townsend L, Dyer AH, Jones K, Dunne J, Mooney A, Gaffney F, et al. Persistent fatigue following SARS-CoV-2 infection is common and independent of severity of initial infection. *PloS One*.

- 2020;15(11):e0240784.
70. Wu C, Hu X, Song J, Yang D, Xu J, Cheng K, et al. Mental health status and related influencing factors of COVID-19 survivors in Wuhan, China. *Clin Transl Med*. 2020 Jun;10(2):e52.
71. Yan N, Wang W, Gao Y, Zhou J, Ye J, Xu Z, et al. Medium Term Follow-Up of 337 Patients With Coronavirus Disease 2019 (COVID-19) in a Fangcang Shelter Hospital in Wuhan, China. *Front Med*. 2020;7:373.
72. Cai X, Hu X, Ekumi IO, Wang J, An Y, Li Z, et al. Psychological Distress and Its Correlates Among COVID-19 Survivors During Early Convalescence Across Age Groups. *Am J Geriatr Psychiatry Off J Am Assoc Geriatr Psychiatry*. 2020 Oct;28(10):1030–9.
73. Liu D, Baumeister RF, Veilleux JC, Chen C, Liu W, Yue Y, et al. Risk factors associated with mental illness in hospital discharged patients infected with COVID-19 in Wuhan, China. *Psychiatry Res*. 2020 Oct;292:113297.
74. Wang X, Xu H, Jiang H, Wang L, Lu C, Wei X, et al. Clinical features and outcomes of discharged coronavirus disease 2019 patients: a prospective cohort study. *QJM Mon J Assoc Physicians*. 2020 Sep 1;113(9):657–65.
75. Carfi A, Bernabei R, Landi F, Gemelli Against COVID-19 Post-Acute Care Study Group. Persistent Symptoms in Patients After Acute COVID-19. *JAMA*. 2020 Aug 11;324(6):603–5.
76. Einvik G, Dammen T, Ghanima W, Heir T, Stavem K. Prevalence and Risk Factors for Post-Traumatic Stress in Hospitalized and Non-Hospitalized COVID-19 Patients. *Int J Environ Res Public Health*. 2021 Feb 20;18(4).
77. Logue JK, Franko NM, McCulloch DJ, McDonald D, Magedson A, Wolf CR, et al. Sequelae in Adults at 6 Months After COVID-19 Infection. *JAMA Netw Open*. 2021 Feb 1;4(2):e210830.
78. Ferrucci R, Dini M, Groppo E, Rosci C, Reitano MR, Bai F, et al. Long-Lasting Cognitive Abnormalities after COVID-19. *Brain Sci*. 2021 Feb 13;11(2).
79. Munn Z, Moola S, Lisy K, Riitano D, Tufanaru C. Methodological guidance for systematic reviews of observational epidemiological studies reporting prevalence and cumulative incidence data. *Int J Evid Based Healthc*. 2015 Sep;13(3):147–53.
80. National Institute for Health and Care Excellence. Depression in adults: recognition and management [Internet]. NICE; 2009. Available from: https://www.google.com/url?q=https://www.nice.org.uk/guidance/cg90&sa=D&source=editors&ust=1619725219629000&usq=AOvVaw1tT0voqXMqvnw1gHPo_Z7b
81. National Institute for Health and Care Excellence. Generalised anxiety disorder and panic disorder in adults: management [Internet]. NICE; 2011 [cited 2021 Apr 28]. Available from: <https://www.nice.org.uk/guidance/cg113>
82. Montgomery P, Dennis J. Cognitive behavioural interventions for sleep problems in adults aged 60+. *Cochrane Database Syst Rev*. 2003;(1):CD003161.
83. Bisson JI, Roberts NP, Andrew M, Cooper R, Lewis C. Psychological therapies for chronic post-traumatic stress disorder (PTSD) in adults. *Cochrane Database Syst Rev*. 2013 Dec 13;(12):CD003388.
84. Heine M, van de Port I, Rietberg MB, van Wegen EEH, Kwakkel G. Exercise therapy for fatigue in multiple sclerosis. *Cochrane Database Syst Rev*. 2015 Sep 11;(9):CD009956.
85. Williams AC de C, Eccleston C, Morley S. Psychological therapies for the management of chronic pain (excluding headache) in adults. *Cochrane Database Syst Rev*. 2012 Nov 14;11:CD007407.
86. Brightling C, Wain L, Evans R, Sundari Devi Dasi A. Long-term follow up of adults hospitalised with COVID19 [Internet]. ISRCTN; [cited 2021 Apr 23]. Available from: <http://www.isrctn.com/ISRCTN10980107>

Anxiety
Depression
Mania
Sensorimotor*
Dizziness/vertigo
Sleep changes
Objectively measured cognitive dysfunction
Subjectively reported cognitive dysfunction
Headache
Reduced taste
Reduced smell
Speech or language difficulty
Hallucinations
Fatigue
Panic
Post-traumatic stress disorder/symptoms

Box 1. Neuropsychiatric symptoms recorded in this review (adapted from Davis et al).

** Includes paraesthesia, numbness, or weakness of specific body parts*

Figure 1. PRISMA Flowchart.




Figure 2. Map of studies

medRxiv preprint doi: <https://doi.org/10.1101/2021.04.30.21256413>; this version posted May 4, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license.

Created with mapchart.net







Figure 3. Forest plots for individual neuropsychiatric symptoms


medRxiv preprint doi: <https://doi.org/10.1101/2021.04.30.21256413>; this version posted May 4, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license.




Proportion of patients objectively identified as having cognitive dysfunction in long covid




Proportion of patients with anxiety in long covid




Proportion of patients reporting PTSD/PTSS in long covid





Proportion of patients subjectively reporting cognitive dysfunction in long covid






Proportion of patients reporting dysnosmia in long covid





Proportion of patients reporting sensorimotor dysfunction in long covid



Proportion of patients reporting dizziness or vertigo in long covid




Figure 4. Pooled symptom prevalence by subgroups

AmedRxiv preprint doi: <https://doi.org/10.1101/2021.04.30.21256413>; this version posted May 4, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license.







Figure S1. Histogram of study quality scores

medRxiv preprint doi: <https://doi.org/10.1101/2021.04.30.21256413>; this version posted May 4, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license.





Figure S2.
Scatterplots of
symptom
prevalence over
time
(dichotomised at
12 weeks)

Prevalence



Definition of Day 0

- PCR or symptom
- ▲ discharge

Time in Weeks

A'





Figure S3.
Scatterplots of
symptom
prevalence over
time
(continuous).

A''



Population characteristics (n = # of patients)		
Sample size (range, median)	n	%
	24-5879, 134	-
COVID-19 confirmed by PCR	15786/18917	83.4
Age (mean, SD)	50.9, 9.4	-
Sex		
Male	6825	33.2
Female	6213	32.8
Unstated	5879	31.1
Location of COVID-19 treatment		
Hospital	9970	52.7
Community	2957	15.7
Mixed or Unstated	5990	31.5
COVID-19 Severity		
ICU / WHO critical-sev	1245	6.6
Hospitalised unspecified	8725	46.1
Community only	2957	15.6
Mixed or Unstated	5990	31.7
Ethnicity		
Stated	2378	12.6
Unstated	16539	87.4
Among stated		
White	1172	49.3
Asian	210	8.8
Black	182	7.7
Mixed / multiple	8	0.3
Hispanic	272	11.4
Other (Arab or other)	534	22.5
Study Characteristics (n= # of studies)		
Study design	n	%
Cohort	43/51	84.3

Cross-sectional	8/51	15·7
Has control group	3/51	5·9
Follow-up duration (range, mean)	14-182, 77	-
COVID19 time-point		
<12 weeks	30/51	58·8
12+ weeks	19/51	37·3
Unstated	2/51	3·9
Definition of follow-up duration		
Post-discharge	23/51	45·1
Post-PCR & post-symptom onset	16/51	31·4
Other	11/51	21·6
Unspecified	2/51	3·9

Table 1. Characteristics of included studies.

Symptom	N studies	N subjects	Pooled prevalence	95% CI	I ²
Fatigue	32	7501	0·244	[0·175, 0·329]	98·0 %
Dysosmia	18	4738	0·114	[0·082, 0·156]	93·1 %
Dysgeusia	18	4675	0·074	[0·047, 0·114]	94·8 %
Depression	16	10402	0·129	[0·075, 0·215]	98·6 %
Headache	15	4023	0·066	[0·036, 0·12]	95·2 %
Anxiety	14	3716	0·191	[0·133, 0·268]	95·8 %
Sleep problems	12	4991	0·274	[0·214, 0·344]	95·6 %
Subj. cog. dysf.	12	2336	0·153	[0·089, 0·25]	95·8 %
PTSD/PTSS	9	2545	0·157	[0·099, 0·241]	95·3 %
Dizziness	8	3665	0·029	[0·016, 0·051]	85·3 %
Obj. cog. dysf.	6	727	0·202	[0·103, 0·357]	93·2 %
Sensorimotor	5	607	0·055	[0·024, 0·123]	79·6 %

Table 2. Pooled prevalence of individual neuropsychiatric symptoms (data for Fig 3). Symptoms are ranked according to the number of studies reporting them.

Table 3. Pooled symptom prevalence by subgroups (data for Fig 4).

Subgroup analysis	Symptom	Subgroup	N studies	N subjects	Pooled prevalence	95% CI
Hospitalisation status	Anxiety	hospitalised	14	3555	0·187	[0·131, 0·261]
		non-hospitalised	2	161	0·422	[0·348, 0·500]
	Depression	hospitalised	14	3419	0·123	[0·070, 0·207]
		non-hospitalised	2	560	0·088	[0·052, 0·147]
	Sleep problems	hospitalised	10	4594	0·276	[0·206, 0·358]
		non-hospitalised	2	161	0·366	[0·296, 0·444]
	Subj cog dysf	hospitalised	8	1659	0·195	[0·109, 0·325]
		non-hospitalised	2	199	0·100	[0·049, 0·193]
	Dizziness	hospitalised	5	3220	0·038	[0·021, 0·068]
		non-hospitalised	2	290	0·021	[0·009, 0·045]
	Headache	hospitalised	10	3049	0·051	[0·024, 0·106]
		non-hospitalised	2	283	0·106	[0·075, 0·148]
	Fatigue	hospitalised	23	5112	0·268	[0·183, 0·375]
		non-hospitalised	3	386	0·214	[0·156, 0·286]
	PTSD/PTSS	hospitalised	9	1926	0·154	[0·098, 0·233]
		non-hospitalised	3	619	0·153	[0·060, 0·337]
Severity	Anxiety	ITU / critical / severe	3	220	0·414	[0·241, 0·611]
		non-ITU	3	443	0·214	[0·088, 0·437]
	Sleep problems	ITU / critical / severe	4	264	0·292	[0·24, 0·349]

		non-ITU	3	1814	0·260	[0·241, 0·281]
	Subj cog dysf·	ITU / critical / severe	3	83	0·277	[0·192, 0·383]
		non-ITU	3	271	0·316	[0·211, 0·444]
	Headache	ITU / critical / severe	2	184	0·016	[0·005, 0·049]
		non-ITU	2	1680	0·018	[0·013, 0·025]
	Fatigue	ITU / critical / severe	6	383	0·335	[0·102, 0·692]
		non-ITU	5	625	0·246	[0·053, 0·655]
	Dysgeusia	ITU / critical / severe	3	173	0·075	[0·044, 0·125]
		non-ITU	3	1814	0·073	[0·062, 0·086]
	Dysosmia	ITU / critical / severe	4	264	0·098	[0·068, 0·141]
		non-ITU	3	1814	0·104	[0·091, 0·119]
Time since discharge	Anxiety	<12 weeks	10	2537	0·170	[0·116, 0·242]
		12+weeks	2	672	0·200	[0·040, 0·601]
	Depression	<12 weeks	9	2304	0·118	[0·051, 0·252]
		12+weeks	3	710	0·147	[0·045, 0·387]
	Sleep problems	<12 weeks	3	674	0·362	[0·241, 0·504]
		12+weeks	4	2496	0·259	[0·199, 0·330]
	Headache	<12 weeks	4	624	0·066	[0·013, 0·280]
		12+weeks	4	2086	0·029	[0·004, 0·178]
	Fatigue	<12 weeks	11	2817	0·254	[0·101, 0·506]
		12+weeks	7	1074	0·268	[0·161, 0·412]

	Dysgeusia	<12 weeks	3	334	0·048	[0·015, 0·147]
		12+weeks	5	2220	0·066	[0·057, 0·077]
	Dysosmia	<12 weeks	3	334	0·061	[0·025, 0·141]
		12+weeks	5	2256	0·080	[0·056, 0·112]
	PTSD/PTSS	<12 weeks	5	1202	0·179	[0·116, 0·266]
		12+weeks	2	358	0·180	[0·036, 0·563]
Time since symptom onset	Headache	<12 weeks	4	571	0·115	[0·051, 0·238]
		12+weeks	3	742	0·066	[0·050, 0·086]
	Fatigue	<12 weeks	5	1015	0·235	[0·125, 0·400]
		12+weeks	5	634	0·197	[0·139, 0·272]
	Dysgeusia	<12 weeks	2	254	0·049	[0·014, 0·163]
		12+weeks	5	908	0·105	[0·058, 0·182]
	Dysosmia	<12 weeks	2	254	0·177	[0·135, 0·230]
		12+weeks	5	935	0·158	[0·118, 0·208]